A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
NCT ID: NCT06195228
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
800 participants
INTERVENTIONAL
2020-01-01
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected.
The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
NCT07010393
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
NCT06062563
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06145308
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
NCT05816642
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
NCT04521348
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Radioiodine-refractory differentiated thyroid cancer
advanced or metastatic thyroid cancer patients who are refractory to radioiodine treatment
dabrafenib plus trametinib with or without PD-1 antibody
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibody
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibody
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the target
Advanced thyroid cancer patients who had other treatment targets not included above
Differentiated thyroid carcinoma not suitable for radioiodine therapy
advanced or metastatic differentiated thyroid cancer patients who are not suitable for radio iodine therapy, for example, DTC patients with huge neck tumor but cannot receive the thyroid ectomy
dabrafenib plus trametinib with or without PD-1 antibody
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibody
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibody
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the target
Advanced thyroid cancer patients who had other treatment targets not included above
Medullary thyroid cancer
patients with advanced or metastatic medullary thyroid cancer
dabrafenib plus trametinib with or without PD-1 antibody
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibody
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibody
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the target
Advanced thyroid cancer patients who had other treatment targets not included above
High-grade or poorly differentiated thyroid cancer
patients with advanced or metastatic High-grade or poorly differentiated thyroid cancer
dabrafenib plus trametinib with or without PD-1 antibody
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibody
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibody
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the target
Advanced thyroid cancer patients who had other treatment targets not included above
Anaplastic thyroid cancer
patients with anaplastic thyroid cancer
dabrafenib plus trametinib with or without PD-1 antibody
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibody
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibody
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the target
Advanced thyroid cancer patients who had other treatment targets not included above
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dabrafenib plus trametinib with or without PD-1 antibody
advanced thyroid cancer patients who harbor BRAF V600E mutation
entrectinib or larotrectinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor NTRK mutation
pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
anlotinib or anlotinib plus anti-PD-1 antibody
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
lenvatinib plus anti-PD-1 antibody
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Other Targets: precise treatment based on the target
Advanced thyroid cancer patients who had other treatment targets not included above
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
3. Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements:
1. Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC);
2. Differentiated thyroid carcinoma not suitable for iodine therapy;
3. Medullary thyroid carcinoma (MTC);
4. poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC);
4. Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment.
Exclusion Criteria
2. There is evidence that the patients are pregnant or lactating;
3. Other situations that are not suitable for inclusion in this study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Shanxi Province Cancer Hospital
OTHER
Henan Cancer Hospital
OTHER_GOV
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Zhejiang Cancer Hospital
OTHER
The Affiliated Hospital of Inner Mongolia Medical University
OTHER
Ruijin Hospital
OTHER
Fujian Cancer Hospital
OTHER_GOV
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Shanghai 6th People's Hospital
OTHER
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
OTHER
Shanghai 10th People's Hospital
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Changhai Hospital
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Jiangsu Cancer Institute & Hospital
OTHER
The First Affiliated Hospital of Anhui University of Chinese Medicine
OTHER
Hunan Provincial People's Hospital
OTHER
Dalian Friendship Hospital Affiliated to Dalian Medical University
UNKNOWN
The Third Affiliated Hospital of Soochow University
OTHER
Sun Yat-sen University
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Sir Run Run Shaw Hospital
OTHER
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ji Dongmei
Associated Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dongmei Ji, M.D
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Yu Wang, M.D
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Qinghai Ji, M.D
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Yansong Lin, M.D
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Cancer Hospital
Fuzhou, Fujian, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Caixia Liu
Hohhot, Inner Mongolia, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital
Shanxi, Taiyuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Peking union medical college hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
M.D
Role: backup
Liang Guo
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FUSCC-TC-RWS01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.